[Radiotherapy in multiple modality treatment of children with nephroblastoma]

Area of Science:

• Pediatric Oncology
• Radiation Oncology
• Nephroblastoma Research

Context:

• Wilms' tumor (nephroblastoma) is a significant pediatric malignancy.
• Multimodality treatment, including radiotherapy, is standard for advanced stages (III-IV).
• Understanding radiotherapy's role in survival and relapse is critical for optimizing treatment.

Purpose:

• To evaluate the efficacy and outcomes of radiotherapy in children with advanced Wilms' tumor.
• To analyze the impact of prognostic factors, including radiation dose and timing, on patient survival and relapse rates.
• To identify potential strategies for dose reduction without compromising survival.

Summary:

• A study of 225 children with stage III-IV Wilms' tumor assessed radiotherapy's role, with 97.3% receiving abdominal irradiation (mean 28 Gy).
• Relapses occurred in 34.2%, and 30.2% died; however, 35.1% survived >5 years.
• Delayed radiotherapy (>1 month post-surgery) increased abdominal relapse risk (21.9%). Reduced doses (≤21.6 Gy) showed no survival detriment, suggesting potential for dose optimization.

Impact:

• Findings support radiotherapy's vital role in advanced Wilms' tumor management.
• Highlights the importance of timely radiotherapy administration to minimize relapse.
• Suggests that reduced radiotherapy doses may be feasible for some patients, potentially minimizing long-term side effects.